Key market metrics for Procter & Gamble Health (PGHL) listed on NSE. For pharmaceuticals sector companies, these metrics provide a snapshot of Procter & Gamble Health's market valuation and enterprise value, essential for comparing against intrinsic value estimates.
We analyze Procter & Gamble Health using multiple valuation models appropriate for PHARMACEUTICALS companies. For PHARMACEUTICALS companies, we use P/E Ratio Analysis, Discounted Cash Flow (DCF), and EPS Growth Valuation to determine fair value estimates for Procter & Gamble Health stock.
10-year Price-to-Earnings ratio trend
Current P/E Ratio
43.26
Jun 03, 2026
5-Year Median P/E
40.37
5-Year Historical Median
Difference
2.89
7.2%
Analysis: Procter & Gamble Health's current P/E ratio is within 10% of its 5-year median (7.2% above), suggesting the stock is fairly valued relative to its historical earnings performance.
The P/E ratio measures how much investors pay for each rupee of earnings (Share Price / EPS). A higher PE suggests the market expects strong future growth, while a lower PE may indicate undervaluation or slower growth prospects. Compare Procter & Gamble Health's current PE against its historical median and PHARMACEUTICALS peers to gauge whether the stock is trading at a premium or discount relative to its earnings.
Go beyond charts — get fair value estimates from multiple valuation models and detailed assessment breakdowns.
Just ₹833/month
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025